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Edited by Stuart FergusonAbstract Angiotensin-converting enzyme-2 (ACE2) is a regula-
tory protein of the renin–angiotensin system (RAS) and a recep-
tor for the causative agent of severe-acute respiratory syndrome
(SARS), the SARS-coronavirus. We have previously shown that
ACE2 can be shed from the cell surface in response to phorbol
esters by a process involving TNF-a converting enzyme (TACE;
ADAM17). In this study, we demonstrate that inhibitors of cal-
modulin also stimulate shedding of the ACE2 ectodomain, a pro-
cess at least partially mediated by a metalloproteinase. We also
show that calmodulin associates with ACE2 and that this inter-
action is decreased by calmodulin inhibitors.
 2007 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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Angiotensin-converting enzyme-2 (ACE2) is rapidly emerg-
ing from the shadow of its better-known homologue angioten-
sin-converting enzyme (ACE) as an important co-regulator of
the renin–angiotensin system (RAS). Whilst the primary phys-
iological role of ACE in the RAS is to hydrolyse angiotensin I
(Ang I) to the potent vasoconstrictor angiotensin II (Ang II)
[1], ACE2 is able to cleave Ang II to produce Ang (1–7), a pep-
tide which has opposing eﬀects [2,3]. The physiological signif-
icance of ACE2 in the RAS has been demonstrated in a variety
of tissues including the heart, liver, kidney and lung [4–7]. In
addition, ACE2 is the cellular receptor for the SARS corona-
virus, the causative agent of severe-acute respiratory syndrome
(SARS) [8]. ACE2, like ACE, is a type I transmembrane metal-
lopeptidase with an extracellular ectodomain containing its
zinc-coordinating catalytic site [9,10]. Here, it is positioned
to hydrolyse circulating substrates and serve as a viral recep-
tor. Regulation of its expression at the cell surface is thereforeAbbreviations: ACE, angiotensin-converting enzyme; ADAM, a disin-
tegrin and metalloproteinase; Ang, angiotensin; CaMi, calmodulin
inhibitor; Dnp, dinitrophenyl; HEK, human embryonic kidney; Mca,
7-amido-4-methylcoumarin; RAS, renin–angiotensin system; RIPA,
radio-immunoprecipitation assay; SARS, severe-acute respiratory
syndrome; TNF-a, tumour necrosis factor-alpha
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doi:10.1016/j.febslet.2007.11.085of prime importance to its physiological and pathophysiologi-
cal functions.
We have previously shown that the ACE2 ectodomain can
be cleaved from the cell membrane and be released into the
extracellular milieu [11,12]. This shedding event is stimulated
by phorbol esters and involves a member of the ADAM (a dis-
integrin and metalloproteinase) family, ADAM17 (also known
as TNF-a-converting enzyme, TACE) [12]. The function of di-
verse cell surface proteins is regulated by such shedding events,
including enzymes (ACE, beta-site amyloid precursor protein
cleaving enzyme), cytokines and growth factors (TNF-a, hep-
arin binding epithelial growth factor) and neurodegenerative
proteins (amyloid precursor protein, cellular prion protein)
[13–18]. Whilst a great deal is known about the proteases
which mediate these shedding events, the factors regulating
this process still remain unclear. Ectodomain shedding is a
complex event responding to a variety of stimuli (phorbol es-
ters, calcium ionophores, growth factors) and involving a vari-
ety of interacting cellular proteins (protein kinase C, Eve),
depending on the substrate [19–21].
In this study, we have identiﬁed the involvement of calmod-
ulin in the regulation of ACE2 ectodomain shedding. Calmod-
ulin is an ubiquitous calcium binding protein which is known
to bind other transmembrane proteins, including L-selectin
and ACE, and regulate their cell surface expression [22,23].
Here, we show that calmodulin interacts with ACE2, both in
cells expressing ACE2 heterologously and endogenously, and
inhibitors of calmodulin increase the release of the ACE2
ectodomain in a dose- and time-dependent manner. This stim-
ulation of shedding is only partially abrogated by metallopro-
teinase inhibitors, suggesting the involvement of disparate
sheddases. Furthermore, treatment with calmodulin inhibitors
decreases the association between the two proteins, suggesting
the interaction of ACE2 with calmodulin serves to retain cat-
alytically active enzyme in the plasma membrane.2. Materials and methods
2.1. Materials
All standard laboratory reagents were purchased from Sigma (UK)
unless indicated otherwise. Anti-ACE2 polyclonal antibody was pur-
chased from R&D Systems (UK), anti-calmodulin antibody and don-
key anti-goat horseradish-peroxidase conjugated secondary antibodies
were purchased from Sigma (UK). GM6001 was purchased from
Chemicon (UK). The ACE2-speciﬁc ﬂuorescent substrate Mca-
APK(Dnp) was synthesized by Dr. G. Knight (Cambridge University,
UK).blished by Elsevier B.V. All rights reserved.
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HEK-ACE2 cells and Huh7 cells, a human hepatocellular carci-
noma-derived cell line known to express and shed ACE2 [12], were
maintained in Dulbeccos modiﬁed Eagles medium supplemented with
10% (v/v) foetal bovine serum, 2 mM essential amino acids, 100 U/ml
penicillin and 100 lg/ml streptomycin.
2.3. Treatment of cells and protein extraction
Cells were grown to conﬂuence in 80 cm3 ﬂasks and rinsed twice with
OptiMem prior to experimentation. All pharmacological treatments
were diluted in OptiMem (5 ml) and all incubations carried out at
37 C. Medium was harvested and concentrated by centrifugation in
10 kDa cut-oﬀ Centricon tubes (VivaScience, UK) to a ﬁnal volume
of 200 ll. Cells were scraped into ice-cold phosphate-buﬀered saline,
pelleted by centrifugation and solubilised in 500 ll radio-immunopre-
cipitation assay (RIPA) buﬀer (0.1 M Tris–HCl, pH 7.4, 0.15 M NaCl,
1% (v/v) Triton X-100, 0.1% (v/v) Nonidet P-40). Protein concentra-
tion was determined using bicinchoninic acid with bovine serum albu-
min as a standard [21].
2.4. Immunoprecipitation of cell lysates
Cell lysates (500 lg, prepared as described) were incubated with
rotation for 3 h at 4 C with 50 ll protein-A Sepharose beads (Sigma).
Following centrifugation, the supernatant was incubated overnight at
4 C with rotation in the presence of 10 ll anti-calmodulin monoclonal
antibody (Sigma). Subsequently, 50 ll protein-A sepharose beads (1 g
resuspended in 3 ml phosphate buﬀered saline) were added and incuba-
tion continued for a further 2 h. The conjugated beads were pelleted by
centrifugation and rinsed three times in ice-cold RIPA buﬀer. The
beads were then heated in SDS–PAGE sample buﬀer containing dena-
turing reagent (Invitrogen) for 10 min at 95 C.
2.5. SDS–PAGE and immunoblotting
Immunoprecipitated proteins were separated by SDS–PAGE and
proteins electrotransferred to nitrocellulose membranes (Invitrogen).
Non-speciﬁc protein binding sites were blocked using 5% (w/v) dried
milk, 3% (w/v) bovine serum albumin in Tris-buﬀered saline containing
0.5% (v/v) Tween-20 (TBS-T), and the membranes subsequently incu-A
B
Fig. 1. ACE2 interacts with calmodulin. (A) Software analysis of the cytopl
presence of a calmodulin binding motif (bold, highlighted in red) proximal to
in humans, mice and rats. (B) Cell lysates collected from untransfected HE
immunoprecipitated with an anti-calmodulin antibody or IgG (referred to as
cells were treated with the calmodulin inhibitor W-7 (25 lM) for 30 min, lysat
before being immunoblotted for ACE2. A blot representative of the results of
analysis performed on the blot, ±S.E.M. *P < 0.05.bated in anti-ACE2 antibody (1:1000 for HEK-ACE2, 1:100 for Huh7)
in the same solution for 3 h. Donkey anti-goat horseradish peroxidase-
conjugated secondary antibody was used at a dilution of 1:5000 for 1 h
in TBS-T. Immunoreactive bands were visualised using enhanced
chemiluminescence (ECL; Pierce, UK) according to the manufacturers
instructions.
2.6. Fluorogenic assay of ACE2
The catalytic activity of ACE2 in concentrated media proteins
(20 lg, HEK-ACE2; 50 lg, Huh7) was determined using a speciﬁc
ﬂuorogenic substrate (Mca-APK(Dnp)), as described previously [12].
2.7. Statistical analyses
Statistical signiﬁcance of data were tested using Mann–Whitney
U-test.3. Results
3.1. The cytoplasmic domain of ACE2 contains a conserved
predicted calmodulin binding motif
Analysis of the cytoplasmic domain of ACE2 using the Cal-
modulin Target Database (http://calcium.uhnres.utoronto.ca;
[24]) revealed the presence of a region strongly indicative of
a potential calmodulin binding domain (Fig. 1A). This 10 ami-
no acid region, encompassing residues 763–772, is evolution-
arily conserved in both rat and mouse (Fig. 1A), suggesting
this domain may be functionally signiﬁcant.
3.2. Calmodulin associates with ACE2
In order to ascertain whether the predicted calmodulin bind-
ing domain of ACE2 was indeed functional, we next per-
formed immunoprecipitation using an anti-calmodulin
monoclonal antibody in cellular lysates collected fromC
asmic domain of ACE2 (http://calcium.uhnres.utoronto.ca) reveals the
the transmembrane domain (italics). The sequence is highly conserved
K293 cells or cells stably transfected with ACE2 (HEK-ACE2) were
IP) and immunoblotted for ACE2 (referred to as WB). (C) HEK-ACE2
es collected and immunoprecipitated with an anti-calmodulin antibody
three experiments is shown together with the results of densitometrical
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Fig. 2. Inhibition of calmodulin increases ACE2 ectodomain shedding. HEK-ACE2 cells (A) or Huh7 cells (B) were incubated in the presence or
absence of calmidazolium (25 lM; CaMi) for 30 min in OptiMem. HEK-ACE2 cells were incubated in the presence (closed circles) or absence (open
circles) of CaMi (25 lM) for the times indicated (C), or for 30 min at the concentrations indicated (D). Media was collected, concentrated and
assayed for ACE2 activity as described in Section 2. The results represent data collected from at least three independent experiments, ±S.E.M.
*P < 0.05.
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Subsequent immunoblotting of immunoprecipitates for
ACE2 revealed a band of the expected size (120 kDa) in
HEK-ACE2 cells but not untransfected HEK cells (Fig. 1B)
or HEK-ACE2 cell lysates subjected to immunoprecipitation
with mouse IgG. Similar results were obtained for Huh7 cells,
which endogenously express ACE2 ([12]; data not shown).
Incubation of HEK-ACE2 cells with W-7, a speciﬁc calmodu-
lin antagonist, reduced the ACE2:calmodulin association
(Fig. 1C).
3.3. Calmodulin inhibitors stimulate ACE2 ectodomain shedding
Given that interaction of membrane proteins with calmodu-
lin has been shown to inﬂuence their retention in the plasma
membrane, we next analysed the eﬀect of inhibiting the associ-
ation of ACE2 with calmodulin on the shedding of its ectodo-
main. Incubation of HEK-ACE2 or Huh7 cells with the
calmodulin antagonist (CaMi) calmidazolium resulted in in-
creased ACE2 activity in the media (Fig. 2A and B, respec-
tively). This CaMi-mediated stimulation of ACE2 shedding
was time- and dose-dependent (Fig. 2C and D, respectively).
Similar results were obtained with other calmodulin inhibitors
(triﬂuoperazine, W-7; data not shown).
3.4. CaMi-stimulated shedding is reduced by the
metalloproteinase inhibitor, GM6001
We have previously demonstrated that ADAM17 (also
known as TACE, tumour necrosis factor-a converting enzyme)
is involved in mediating stimulated ACE2 shedding in responseto phorbol ester [12]. We therefore next analysed whether a
metalloproteinase is also involved in CaMi-stimulated ACE2
shedding. Pre-incubation of HEK-ACE2 cells with the
hydroxamate-derived metalloproteinase inhibitor GM6001 re-
duced the increased ACE2 shedding in response to CaMi
(Fig. 3A). GM6001 treatment had little eﬀect on basal shed-
ding of ACE2 from HEK-ACE2 cells as shown previously
[12]. Inhibitors of other classes of proteinases (serine, aspartic
and cysteine) had no observable eﬀect on shedding (Fig. 3B).
GM6001 did not have any eﬀect on the activity of ACE2 itself
(Fig. 3C).4. Discussion
ACE2 is increasingly recognised to have a pivotal role in reg-
ulating the local levels of the hypertensive and mitogenic pep-
tide angiotensin II [25–27]. In addition, it is also the cellular
receptor of the causative agent of SARS, SARS-CoV [8].
ACE2 is a type I transmembrane protein which is subject to
a juxtamembrane cleavage event releasing a catalytically active
ectodomain [12]. While the precise physiological role of this
shedding event is unknown it is clear, given the well docu-
mented pathophysiological roles of Ang II, that the mecha-
nisms regulating the cell surface expression of ACE2 are of
critical importance. We have previously demonstrated that
the shedding of ACE2 can be stimulated by phorbol ester, a
process mediated at least in part by the promiscuous metallo-
proteinase sheddase, ADAM 17 [12]. Here, we show that the
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Fig. 3. CAMi-mediated ectodomain shedding is blocked by metalloproteinase inhibitor. HEK-ACE2 cells were pre-incubated with either the
sheddase inhibitor GM6001 (25 lM); (A and C) or the cysteine proteinase inhibitors E-64 and leupeptin, the serine proteinase inhibitor 3,4-
dichloroisocoumarin or the aspartic proteinase inhibitor pepstatin A (B) for 30 min before the addition of CaMi (25 lM) for 30 min. Media from
these and from untreated control cells was collected, concentrated and assayed for ACE2 activity as described in Section 2. As an additional control,
media were collected from untreated cells and incubated in the presence or absence of 50 lM GM6001 before being assayed for ACE2 activity as
described. The results are presented relative to untreated control ﬂasks and represent data collected from four (A), two (B) or three (C) independent
experiments. *P < 0.1.
Fig. 4. The ACE2 homologue collectrin contains a putative calmodulin binding motif. Alignment of human somatic ACE, ACE2 and collectrin
functional domains. Stars indicate catalytic sites, black rectangles the transmembrane domains and white rectangles denote observed (*) or predicted
calmodulin binding domains. The ACE2 and collectrin peptide sequence alignment shows conserved residues (highlighted) and predicted calmodulin
binding domain (outlined). There is no homology between ACE and ACE2 or collectrin in this region. The transmembrane hydrophobic regions of
all three proteins are in italics.
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D.W. Lambert et al. / FEBS Letters 582 (2008) 385–390 389shedding of ACE2 can also be upregulated by inhibitors of the
ubiquitous calcium binding protein, calmodulin, both in cells
endogenously expressing ACE2 (Huh7) and in those heterolo-
gously over-expressing it (HEK-ACE2). The CaMi-mediated
increase in ACE2 shedding was reduced by the hydroxamate-
derived metalloproteinase inhibitor GM6001, suggesting the
involvement of an ADAM (a disintegrin and metalloprotein-
ase). Inhibitors of other classes of proteinases (serine, aspartic,
and cysteine) had no eﬀect on cleavage. Further studies are re-
quired to determine whether the CaMi-stimulated shedding of
ACE2 is also mediated by ADAM17, or whether phorbol es-
ters and calmodulin inhibitors invoke distinct sheddases.
Computational analysis of the cytoplasmic domain of ACE2
revealed a conserved consensus calmodulin binding motif.
Immunoprecipitation experiments revealed that calmodulin
associates with ACE2 suggesting that this motif may be func-
tional. While further studies are required to elucidate the pre-
cise binding site of calmodulin on ACE2, these results clearly
indicate that association of calmodulin with ACE2 has a regu-
latory role in its cleavage-secretion from the plasma mem-
brane. It is noteworthy that the cytoplasmic tail of ACE2 is
quite distinct to that of ACE, the shedding of which is also
modulated by association with calmodulin [23]; however, the
ACE2 tail bears signiﬁcant sequence identity to collectrin, a
developmentally regulated protein recently shown to have a
critical role in amino acid retrieval in the kidney [28,29]
(Fig. 4). Analysis of the sequence of the cytoplasmic domain
of collectrin also identiﬁes a putative calmodulin-binding motif
(Fig. 4). Recent studies have revealed that collectrin is also
subject to ectodomain shedding [30], suggesting a possible role
for calmodulin in regulating the cell surface expression and re-
lease of this protein.
In summary, we have demonstrated that ACE2 interacts
with calmodulin and that this association down-regulates shed-
ding of the ACE2 ectodomain. This is the ﬁrst study to identify
a regulatory binding protein for ACE2 in vitro, revealing a
hitherto unknown mechanism for regulating its cell surface
and circulating activity.
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